Global efforts to reform product development for neglected diseases are failing, a launch of a five-year review of funding of research and development for these diseases, heard today.
The report shows that overall funding has stagnated since 2007, at a time when increases are needed, the launch heard. In addition, a recent trend of higher industry funding for commercially viable diseases may lead to a two-tier, two-speed system, in which products for some diseases get left behind, according to Mary Moran, director of the Policy Cures think-tank and the report's lead author.
She presented findings showing that, while up to 70 per cent of global R&D funding for 'semi-commercial' diseases such as dengue and tuberculosis goes towards product development, only 45 per cent of such funding for diseases reliant on public funding goes on product development.
To read the full, original article click on this link: R&D funding for neglected diseases 'failing' - SciDev.Net
